Dose-Response Effect of Phosphatidylserine on eSport Performance
ClinicalTrials.gov Studies
Summary
NIH registered a new randomized, double-blind, placebo-controlled clinical trial (NCT07533032) evaluating daily phosphatidylserine supplementation at 100 mg or 200 mg doses in healthy adult gamers over 6 weeks. The study will measure electronic gaming performance, cognitive function, sleep quality, stress outcomes, and heart rate variability at baseline, Week 3, and Week 6. Enrollment includes approximately 75 participants assigned to three parallel groups.
What changed
NIH registered a new clinical trial on ClinicalTrials.gov studying phosphatidylserine supplementation in eSport gamers. The parallel-group, placebo-controlled study will enroll healthy adult gamers and assess outcomes including gaming performance, cognitive function, visual analog scales, sleep quality, hemodynamic responses, and heart rate variability at three timepoints over 6 weeks.
For clinical investigators and trial sponsors, this registration signals interest in supplement-based cognitive and performance interventions for gaming populations. The study targets approximately 75 participants across three arms receiving placebo or phosphatidylserine at two dose levels. Researchers conducting similar gaming or cognitive performance studies should note this competitive landscape and ensure their protocols adequately address the FDA's IND requirements for supplement research.
Archived snapshot
Apr 17, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Dose-Response Effect of Phosphatidylserine on eSport Performance
N/A NCT07533032 Kind: NA Apr 16, 2026
Abstract
This study will evaluate the effects of daily phosphatidylserine supplementation on electronic gaming performance, cognitive function, sleep quality, stress-related outcomes, and autonomic responses in healthy adult gamers. Participants will be enrolled in a randomized, double-blind, placebo-controlled, parallel-group study and assigned to receive placebo, 100 mg phosphatidylserine, or 200 mg phosphatidylserine daily for 6 weeks.
Outcome measures will be assessed at baseline, Week 3, and Week 6 and will include electronic gaming performance, cognitive function, visual analog scale ratings, sleep quality questionnaires, hemodynamic responses, and heart rate variability. The study is designed to determine whether daily phosphatidylserine supplementation can improve performance and selected physiological and psychological outcomes during prolonged electronic gaming sessions.
Conditions: Cognitive Function, Gaming Performance
Interventions: Placebo, Phosphatidylserine (100 mg), Phosphatidylserine (200 mg)
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.